

1 **Ochratoxin A status at birth is associated with reduced birthweight and ponderal index**
2 **in rural Burkina Faso**

3 **Authors:**

4 Yuri Bastos-Moreira,^{1,2} Alemayehu Argaw,² Giulianmichela Di Palma,³ Trenton Dailey-
5 Chwalibóg,² Jasmin El-Hafi,^{1,4} Lionel Olivier Ouédraogo,^{2,5} Laeticia Celine Toe,^{2,6} Sarah De
6 Saeger,^{1,7} Carl Lachat,² and Marthe De Boevre¹

7 **Affiliations:**

8 ¹ Center of Excellence in Mycotoxicology and Public Health, MYTOX-SOUTH[®]
9 Coordination Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium

10 ² Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering,
11 Ghent University, Ghent, Belgium

12 ³ Department of Chemistry, University of Torino, Torino, Italy

13 ⁴ Institute of Food Chemistry, University of Münster, Münster, Germany

14 ⁵ Laboratoire de Biologie Clinique, Centre Muraz, Bobo-Dioulasso, Burkina Faso

15 ⁶ Unité Nutrition et Maladies Métaboliques, Institut de Recherche en Sciences de la Santé
16 (IRSS), Bobo-Dioulasso, Burkina Faso

17 ⁷ Department of Biotechnology and Food Technology, Faculty of Science, University of
18 Johannesburg, Doornfontein Campus, Gauteng, South Africa

19 **Corresponding author**

20 Marthe De Boevre; Ottergemsesteenweg 460, 9000 Ghent, Belgium;

21 Marthe.DeBoevre@UGent.be

22 **Abbreviations:** AFs, aflatoxins; AFB1, aflatoxin B1; AFG1, aflatoxin G1; AFM1, aflatoxin
23 M1; AIC, Akaike Information Criterion; BEP, balanced energy-protein; BIC, Bayesian
24 Information Criterion; BioSpé, Biospecimen; CIT, citrinin; DON, deoxynivalenol; FB1,
25 fumonisin B1; GA, gestational age; IARC, International Agency for Research on Cancer; IFA,
26 iron-folic acid; LAZ, length-for-age z-score; LBW, low birth weight; LMICs, low-and-middle
27 income countries; LOD, limit of detection; LLOQ, lower limit of quantification; MISAME,
28 Micronutriments pour la SANTé de la Mère et de l'Enfant; MUAC, mid-upper arm
29 circumference; OTA, ochratoxin A; PTB, preterm birth; SGA, small-for-gestational age;
30 UPLC-MS/MS, ultra-performance liquid chromatography-tandem mass spectrometry; VAMS,
31 volumetric absorptive microsampling; WAZ, weight-for-age z score; WLZ, weight-for-length
32 z score; ZAN, zearalanone; ZEN, zearalenone.

33 **Abstract**

34 **Background:** Mycotoxin exposure during pregnancy has been associated with adverse birth
35 outcomes and poor infant growth. We assessed multiple biomarkers and metabolites of
36 exposure to mycotoxins at birth and their associations with birth outcomes and infant growth
37 in 274 newborns in rural Burkina Faso.

38 **Methods and findings:** Whole blood microsamples were analyzed for mycotoxin
39 concentrations in newborns in the Biospecimen sub-study nested in MISAME-III trial using
40 ultra performance liquid chromatography coupled to tandem mass spectrometry. Unadjusted
41 and adjusted associations between mycotoxin exposure, and birth outcomes and infant growth
42 at 6 months were estimated using linear regression models for continuous outcomes and linear
43 probability models with robust variance estimation for binary outcomes. Infant growth
44 trajectories from birth to 6 months were compared by exposure status using mixed-effects
45 models with random intercept for the individual infant and random slope for the infant's age.
46 Ochratoxin A (OTA) exposure was detected in 38.3% of newborns, with other mycotoxins
47 being detected in the range of 0.36% and 4.01%. OTA exposure was significantly associated
48 with adverse birth outcomes, such as lower birthweight (β (95% CI): -0.11 kg (-0.21, 0.00); p
49 = 0.042) and ponderal index (β (95% CI): -0.62 gm/cm³ (-1.19, -0.05); p = 0.034), and a
50 marginally significant lower height growth trajectories during the first 6 months (β (95% CI):
51 -0.08 cm/mo (-0.15, 0.0); p = 0.057) .

52 **Conclusions:** OTA exposure was prevalent among newborns and also associated with lower
53 growth at birth and during the first 6 months. The results emphasize the importance of
54 nutrition-sensitive strategies to mitigate dietary OTA, as well as adopting food safety
55 measures in Burkina Faso during the fetal period of development.

56 **Keywords:** birth outcomes, exposomics, growth, low- and middle-income countries,

57 MISAME-III, mycotoxins, sub-Saharan Africa, ochratoxin A

58 **Background**

59 Mycotoxins are toxic fungal secondary metabolites that contaminate a wide spectrum of
60 essential foods worldwide, including staple crops consumed by the most vulnerable populations
61 (1). Foodstuffs in West Africa are commonly affected by mycotoxins (2,3) since the climate,
62 where there is high temperature and humidity, is favorable for their production (4,5). Maternal
63 nutrition affects both the pregnancy's process and the newborn's well-being (6). In low-and
64 middle-income countries (LMICs), adverse pregnancy outcomes are common including low
65 birth weight (LBW), preterm birth (PTB) and/or small-for-gestational age (SGA) (7). Several
66 epidemiological studies have indicated that mycotoxin exposure is extensive in newborns (8–
67 11).

68 The International Agency for Research on Cancer (IARC) categorizes aflatoxin B1 (AFB1) as
69 carcinogenic to humans (Group1), and fumonisin B1 (FB1) and ochratoxin A (OTA) as possible
70 human carcinogens (Group 2B) (12). The human fetus is vulnerable to health effects resulting
71 from *in utero* exposure to environmental chemicals (13). Formerly, higher AF exposure, *in*
72 *utero* and in early life, has been linked with stunting and/or underweight, while children with
73 high fumonisins exposure were also shorter and lighter (14). In addition, research has also
74 shown that OTA can cross the placental barrier in humans (15), and is reported to also have
75 other toxic effects in humans including immunotoxicity and nephrotoxicity (16–18).

76 A literature review by Arce-López *et al.* (2020) concluded that OTA is often detected in whole
77 blood, plasma and serum samples (19). Authors reported frequency levels of 64.9% (20–23),
78 and concluded that the global population is generally exposed to OTA due to its long half-life
79 in these matrices (19). This exposure during the critical first 1,000 days of life (10) might
80 contribute to adverse fetal and infant outcomes (24). Generally, birthweight is an indicator of

81 both maternal health and nutrition status, and also the infant's well-being. Infants born with
82 LBW are at increased risk of several short- and long-term consequences, including neonatal
83 mortality, childhood stunting and impaired immune function (25–27). Nevertheless, research
84 investigating the association between mycotoxins exposure and birth and infant growth
85 outcomes have reported inconsistent results (28–31).

86 In Burkina Faso, limited biological and toxicological food contamination data are available
87 (32), and legislation and regulations regarding mycotoxins are often not implemented (33,34).
88 Using data from the Biospecimen (BioSpé) sub-study of the MISAME-III (MICronutriments
89 pour la SAnité de la Mère et de l'Enfant) trial in rural Burkina Faso, we previously reported a
90 prenatal exposure to multiple mycotoxins among pregnant women from a rural Burkinabé
91 setting, and found no evidence of associations with adverse birth outcomes and infant growth
92 (in publication (35)). In the present study, we aimed to quantify newborn mycotoxin exposure
93 at birth and investigated the association with birth outcomes and infant growth in the same
94 mother-newborn dyads.

95 **Methods**

96 **Study setting, participants, and design**

97 Study protocols for the main MISAME-III trial (36) and the BioSpé sub-study nested under
98 the MISAME-III trial (37) were published previously. The main MISAME-III study is a 2 x 2
99 factorial randomized controlled trial evaluating the effect of balanced energy-protein (BEP)
100 supplementation to mothers during pregnancy (prenatal intervention) and lactation (postnatal
101 intervention) on maternal and child outcomes. In a subsample from the main MISAME-III
102 trial (Figure 1), a BioSpé sub-study was conducted aiming to understand the physiologic
103 mechanisms through which the BEP supplement affects the maternal and child outcomes by

104 way of multi-omics analyses, human biomonitoring of contaminants (mycotoxins, black
105 carbon, gut enteropathogens and pesticides), and analysis of relative telomere length and
106 mitochondrial DNA content (37).

107 The study was conducted in 6 rural health center catchment areas in the district of Houndé in
108 the Hauts-Bassins region of Burkina Faso. The study area is characterized by a Sudano-
109 Sahelian climate with a dry season running between September/October and April, and
110 agricultural activities being the main livelihood of the community. Results from a previously
111 conducted dietary survey in a sub-sample of the MISAME-III pregnant women showed the
112 habitual diet during pregnancy is nondiverse, predominantly based on maize with a
113 complement of leafy vegetables (38). Grains, roots, tubers and plantains together contributed
114 68% of the total calorie intake during pregnancy. Almost all participants (95%) consumed the
115 main staple dish tô, which contributed 42% of the total energy intake. Tô is a stiff maize
116 dough often served with a watery sauce containing green-leafy vegetables (okra, hibiscus, and
117 baobab leaves) or other vegetables such as eggplant, with or without meat, fish, or
118 caterpillars. Other food groups such as fruits, dairy, eggs, fish, and meat contributed very
119 small amounts to the total energy intake (39).

120 **Exposure and outcomes**

121 The present study considered exposure to a range of mycotoxins listed in Table 2. However,
122 aflatoxin B1 (AFB1)-lysine exposure was not assessed due to the current unavailability of the
123 commercial analytical standard for this specific mycotoxin. Mycotoxin exposure was defined
124 as the detection of a concentration \geq the limit of detection (LOD) in whole blood
125 microsamples.

126 The outcomes of interest were birth outcomes, such as birth weight, SGA, LBW, gestational
127 age (GA), PTB, length, mid-upper arm circumference (MUAC), head circumference, ponderal
128 index, chest circumference, and infant growth and nutritional status at the age of 6 months,
129 such as length-for-age z-score (LAZ), weight-for-age z-score (WAZ), weight-for-length z-
130 score (WLZ), MUAC, head circumference, hemoglobin, stunting, underweight, wasting and
131 anemia. We additionally assessed the associations between mycotoxin exposure and infant
132 growth trajectories (height, weight, upper-arm and head circumferences) during the first 6
133 months postpartum.

134 PTB was defined as the birth of a newborn before 37 completed weeks of gestation. SGA was
135 defined as a newborn weight less than the 10th percentile of weight for the same GA and sex
136 according to the International Fetal and Newborn Growth Consortium for the 21st Century
137 (INTERGROWTH-21st) (40). Anthropometric z-scores of LAZ, WAZ and WLZ were
138 calculated based on the WHO Child Growth Standards with stunting, underweight and
139 wasting defined as LAZ, WAZ and WLZ values below 2 SD from the median value for same
140 age and sex from the reference population (41). Newborn Rohrer's ponderal index was
141 calculated as weight in g divided for length in cm cubed (i.e., $\text{weight}/\text{length}^3 \text{ (g/cm}^3\text{)} \times 1,000$).

142 **Data collection**

143 The MISAME-III trial data were collected through computer-assisted personal interviewing
144 using SurveySolutions (version 21.5) on tablets and then transferred to a central server at
145 Ghent University. Sociodemographic and other relevant characteristics of participants and
146 study households were collected at baseline during the first and early second trimester of
147 pregnancy. All newborn anthropometry measurements were taken within 12 hours of birth,
148 whereas mothers were invited for follow-up growth assessment every month until 6 months of

149 age. Measurements were taken in duplicates and a third measurement was taken in case of a
150 large discrepancy between the duplicate measurements. Length was measured to the nearest 1
151 mm with a Seca 416 Infantometer, weight was measured to the nearest 10 g with a Seca 384
152 scale, and head circumference, thoracic circumference and MUAC were measured to the
153 nearest 1 mm with a Seca 212 measuring tape. GA was determined using a portable
154 ultrasound (SonoSite M-Turbo, FUJIFILM SonoSite, Bothell, Washington, USA) during the
155 first and early second trimester of pregnancy.

156 **Blood sample collection and laboratory analysis**

157 Samples collection and lab analysis procedures were described in detail previously (37).
158 Newborn samples were collected between May and October 2021 within 12 hours of birth in
159 all newborns. An amount of 40 of capillary whole blood was collected by capillary sampling
160 onto VAMS tips ($2 \times 20 \mu\text{L}$ VAMS tips), namely MitraTM, via direct heel incision for
161 mycotoxins analysis (37). Then, VAMS tips were stored in 20 μL Mitra Clamshells and
162 transported from the health centers to the Institut de Recherche en Sciences de la Santé in
163 Bobo-Dioulasso, Burkina Faso for shipment at room temperature to the Centre of Excellence
164 in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University,
165 Belgium. For storage at -80°C until analysis, VAMS were placed in Mitra Autoracks (96-
166 Sampler, item number: 108) inside a storage bag containing desiccant bags (item number:
167 AC-SS02). Items used for VAMS collection were purchased from Neoteryx (Torrance,
168 California, USA).

169 A VAMS multi-mycotoxin extraction (42) began by transferring the VAMS tips from the
170 plastic handles into 2 mL Eppendorf tubes, and pipetting 250 μL extraction solvent
171 (acetonitrile/water/acetic acid, 59/40/1, v/v/v), containing the internal standards $^{13}\text{C}_{17}$ -AFB1

172 (0.125 µg/L) and ¹³C₁₅ – deoxynivalenol (DON) (0.25 µg/L), ¹³C₃₄–FB1 (0.25 µg/L) and
173 ¹³C₁₈–zearalenone (ZEN) (0.125 µg/L), to the sample tubes. Subsequently, samples were
174 ultrasonicated for 30 minutes and shaken for 60 minutes at 25°C with rotation at 1,400 rpm in
175 a Biosan TS-100 Thermo-Shaker followed by centrifugation (10 minutes at 10,000g, room
176 temperature). The tips were discarded, and the supernatant was pipetted to an 8 mL glass tube
177 and evaporated under nitrogen on a Turbovap LV Evaporator (Biotage, Charlotte, USA).
178 Afterwards, the extracts were reconstituted in 50 µL of injection solvent (methanol/water,
179 60/40, v/v), vortexed, centrifuged (for 10 min at 5000 g) and filtered (22 µm, PVDF,
180 Durapore[®], Cork, Ireland). Lastly, samples were transferred into vials before 10 µL were
181 injected into an Acquity ultrahigh performance liquid chromatography (UPLC) system
182 (Waters[®], Manchester, UK) equipped with an Acquity HSS T3 100 × 2.1 mm UPLC column
183 (1.8 µm particle size) and Acquity Vanguard HSS T3 10 × 2.1 mm UPLC pre-column (1.8 µm
184 particle size), both from Waters[®] (Manchester, UK). Detailed instrument parameters can be
185 found in a previous study (42).

186 **Statistical analysis**

187 Data management and statistical analyses were performed using Stata (Stata Statistical
188 Software: release 17.0; StataCorp), and a 2-sided statistical significance was considered at *p*
189 <0.05. Descriptive statistics are presented using means ± SD or medians (range) for the
190 continuous variables, depending on the nature of the data distribution, and frequencies
191 (percentages) for nominal variables.

192 In the study sample, only exposure to OTA was found in an adequate number of newborns to
193 assess the association with birth outcomes and infant growth. The association between OTA
194 exposure and the study outcomes at birth and 6 months of age was evaluated using linear

195 regression models for the continuous outcomes and linear probability models with robust
196 variance estimation for the binary outcomes. All models were adjusted for clustering by the
197 health center catchment areas and allocation for the prenatal and postnatal BEP interventions.
198 Furthermore, adjusted models additionally included the covariates maternal age, primiparity,
199 baseline BMI and hemoglobin concentration, household size, wealth index score, access to
200 improved water and sanitation, and food security status.

201 We also compared OTA exposed and non-exposed groups by growth trajectories from birth to
202 6 months. For this purpose, we fitted mixed-effects regression models with random intercept
203 for the individual infant and random slope for the infant's age (months). We explored the best
204 growth trajectory fitting the data by visual inspection of graphs and comparing model fit
205 indices including AIC (Akaike Information Criterion) and BIC (Bayesian Information
206 Criterion) values. Accordingly, we applied quadratic models (for the outcomes height, weight
207 and MUAC) and restricted cubic spline model with 4 knots (for the outcome head
208 circumference). We considered an unstructured covariance matrix for the correlation among
209 repeated measurements within an individual. Fixed effects in the model included the main
210 effect of OTA exposure, the main effect of age, and exposure by age interaction, which the
211 later estimates the difference in monthly changes in the outcome between exposure and
212 unexposed groups. Models were further adjusted for the aforementioned covariates.

213 In a further exploratory analysis, we evaluated potential interactions between OTA exposure
214 and the allocation to the maternal BEP interventions on the study outcomes. For this purpose,
215 interaction terms between OTA exposure and the prenatal and postnatal BEP interventions
216 were specified in the models with the presence of interaction was considered at $p < 0.10$.
217 Lastly, Cohen's weighted kappa test was used to assess the level of agreement between
218 mother-newborn OTA exposure status. Results were reported as percentage agreement and

219 Cohen's weighted kappa values. The following cut-offs were used: Kappa values ≤ 0 no
220 agreement, 0.01–0.20 none to slight, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80
221 substantial, and 0.81–1.00 almost perfect agreement (43).

222 **Results**

223 Mother-newborn dyads characteristics

224 Birth outcomes and infant growth at 6 months were assessed on 274 and 255 newborns,
225 respectively (**Figure 1**). Mean \pm SD age of the mothers was 24.3 ± 5.63 years and 45.3% of
226 mothers had at least a primary education (**Table 1**). The mean \pm SD maternal BMI at study
227 inclusion was 22.1 ± 3.22 kg/m² with 6.93% underweight (BMI < 18.5 kg/m²). More than two-
228 thirds (70.3%) of the newborns were from food insecure households and 29.9% of their
229 mothers were anemic at study enrollment during the first/early second trimester of pregnancy.

230 Mycotoxins exposure and newborn and infant growth and nutritional status

231 The laboratory analysis indicated that, aside from OTA, almost all newborns were found to be
232 not exposed to most mycotoxins (**Table 2**). OTA exposure was detected in 38.3% of the
233 newborns with a median (range) concentration of <LOD (<LOD, 3.61) μ g/L. The LOD for
234 OTA as 0.09 μ g/L. The UPLC-MS/MS chromatograms of OTA are shown in **Figure 3**.

235 Other mycotoxins such as AFB1, aflatoxin G1 (AFG1), aflatoxin M1 (AFM1), DON, citrinin
236 (CIT), zearalanone (ZAN) and ZEN were detected in the range of 0.36% and 4.01% of
237 newborns. For the remaining 26 mycotoxins analyzed, no exposure was detected through
238 whole blood analysis.

239 In the unadjusted models, newborn OTA exposure was found to be negatively associated ($p <$
240 0.05) with birth outcomes, such as birthweight, MUAC, ponderal index and chest

241 circumference, as well as with LAZ at the age of 6 months (**Table 3 & 4**). These associations
242 remained significant after adjustment for relevant covariates only for birth weight (adjusted β
243 (95% CI): -0.11 kg (-0.21, 0.00); $p = 0.042$) and ponderal index (adjusted β (95% CI): -0.62
244 gm/cm³ (-1.19, -0.05); $p = 0.034$). Likewise, newborns who were exposed to OTA had
245 marginally significantly lower height growth trajectories than their counterparts without OTA
246 exposure (adjusted β (95% CI): -0.08 (-0.15, 0.00) cm/month; $p = 0.057$) (**Figure 2**).

247 There was also a significant interaction between newborn OTA exposure status and the
248 maternal prenatal BEP intervention on the outcome child anemia status at 6 months of age
249 ($p_{\text{interaction}} = 0.074$) (**Supplemental Table 1**). OTA exposure was significantly associated with
250 higher anemia prevalence among newborns of mothers who did not receive prenatal BEP
251 supplementation (adjusted β (95% CI): 18.7% (2.00, 35.3); $p = 0.029$), while no significant
252 association was detected among newborns whose mothers received the prenatal BEP
253 supplementation (adjusted β (95% CI): 0.08% (-19.1, 19.3); $p = 0.993$). In the present study,
254 there was a 63.0% agreement between mother-newborn OTA exposure status and the kappa
255 value was classified as fair (Kappa = 0.27).

256 **Discussion**

257 There is a growing concern about the potential adverse health and developmental
258 consequences of fetal mycotoxins exposure. The present study found a high prevalence of
259 OTA exposure (38.32%) amongst newborns at birth. Exposures to mycotoxins, such as
260 AFG1, AFB1, AFM1, CIT, DON, ZAN and ZEN were detected in relatively fewer subjects,
261 whereas other mycotoxins were not detected. Moreover, we found that OTA exposed
262 newborns had significantly lower birthweight and ponderal index than their non-exposed
263 counterparts. OTA exposed newborns also had marginally significantly lower height growth

264 trajectories. Finally, an exploratory analysis indicated that maternal prenatal BEP
265 supplementation may offset the effect of OTA exposure on increased anemia prevalence at 6
266 months of age.

267 This is the first study to report the level of mycotoxins exposure in newborns using whole
268 blood microsamples. OTA is produced predominantly by some *Aspergillus*, *Monascus*, and
269 *Penicillium* species, which frequently contaminates cereals and derived products, dried fruit,
270 coffee, cocoa, spices, wine and cured pork products. Considering that in Burkina Faso maize
271 is the second most cereal produced, the Burkinabé population is often exposed to OTA (44–
272 46). A study in Sierra Leone reported OTA exposure in 25% of cord blood samples in
273 newborns (range: 0.2-3.5 µg/L). However, the study detected a high prevalence of overall
274 exposure to AFB1, AFM1, aflatoxinol, AFB2, AFM2, AFG1 and AFG2 (90.6%), while the
275 present study showed limited exposure to AF except AFB1-lys which was not analyzed (11).
276 The occurrence of OTA detected in the present study is also comparable to previous literature
277 using adult samples. Fan *et al.* (2019) analyzed plasma samples of 260 adults in China and
278 detected OTA in 27.7% of samples (range: 0.31-9.18 µg/L) (21), likewise in another study the
279 OTA prevalence was 28% in serum samples from Tunisia (range: 0.12 and 11.67 µg/L) (22).
280 On the other hand, exposure to mycotoxins other than OTA was found to be low in our study
281 population as compared to what has been reported previously in LMICs (8,23,48,49). The
282 variations in physicochemical properties of mycotoxins can lead to differences in their
283 toxicokinetic profiles, which results in different excretion amounts and times. Therefore, it is
284 conceivable that the used UPLC-MS/MS system may not detect the lowest concentrations of
285 mycotoxin metabolites. Further research is required on mycotoxins' stability during the
286 processing of foodstuffs, their fate in the digestive system as well as toxicodynamic and
287 toxicokinetic studies (50). Additionally, the knowledge of the formation process of these

288 metabolites and the understanding of their structure and molecular mass can solve the
289 analytical and technological challenges associated with these metabolites. Therefore, given
290 these facts, there may be underreporting of exposure to certain mycotoxins due to their short-
291 half lives.

292 The teratogenic effects of OTA have been well reported in animal studies. Reduced birth
293 weight and craniofacial abnormalities are the most frequent reported outcomes (51). Oral
294 administration of OTA at 5 mg/kg body weight to pregnant rats was reported to cause a
295 reduced weight of the fetus as well as frequent hemorrhages (52–54). In addition, a single oral
296 dose of OTA at 4 mg/kg body weight caused abortions, maternal deaths and reduction in
297 maternal and fetal body weights (51). In the present study, results indicated a reduction of
298 0.11 kg in birthweight in newborns exposed to OTA compared to unexposed newborns,
299 though previous findings that OTA exposure is associated with poor birth outcomes and infant
300 growth have been reported inconsistently. In Uganda, AF exposure measured in mid-
301 pregnancy was associated with LBW and smaller head circumference (55). Formerly, Jonsyn
302 *et al.* (1995) also reported that when OTA is present in combination with AFs and their
303 metabolites in cord blood samples, the birth weight is likely to be reduced (47). A study from
304 Ethiopia found an association between chronic maternal AF exposure and lower fetal growth
305 trajectories using fetal biometry from ultrasound estimates. However, the same study did not
306 find an association of AF exposure with birth anthropometry (56). A systematic review of
307 studies that evaluated mycotoxin exposure and infant growth also found inconsistent results
308 (28). With the wide variation in detected mycotoxin concentrations and possible confounding
309 factors adjusted for in these studies, it is not surprising that some found associations and
310 others did not.

311 In contrast, in our previous analysis of OTA exposure during the third trimester of pregnancy
312 in the same cohort, we did not find associations between maternal exposure and growth at
313 birth and at 6 months of age (35). Besides this, we only found a fair level of agreement
314 between maternal OTA exposure during the third trimester of pregnancy (50.8%) and
315 neonatal exposure (38.3%) status ($Kappa = 0.27$). There was also no constant pattern in the
316 type or quantity of AFs or OTA detected in maternal and cord blood samples in other studies.
317 A study in Sierra Leone detected 12.5% OTA exposure in maternal serum samples versus
318 25.5% in cord blood samples (11); while a study in Bolivia detected OTA in 87% in the cord
319 plasma samples versus 12.5% in the maternal plasma samples (57). A potential reason for the
320 higher detection of OTA in the previous prenatal maternal OTA exposure analysis conducted
321 (35) is that it was conducted at 30-34 weeks of gestation, and previous literature have reported
322 that the level of OTA from the mother to the fetus has a higher transfer rate in the earlier
323 stages of pregnancy compared to later (15). Furthermore, OTA distribution in the human body
324 could also be affected by the development of placenta and physiological differences
325 throughout pregnancy (58). Lastly, there could be seasonal variations in mycotoxin exposure
326 status depending on food availability, and storage conditions with the maternal samples were
327 collected between July and March (35) while the newborn samples were collected between
328 May and October.

329 In the previous analysis by de Kok *et al.* (2022) maternal BEP supplementation during
330 pregnancy and lactation were beneficial in reducing the prevalence of LBW, and improving
331 GA, birth weight, birth length and chest circumference (59). However, iron and folic acid
332 supplementation in the form of BEP or IFA tablets formulations did not improve anemia
333 prevalence during pregnancy (60). Similarly, there was a high prevalence of infant anemia at
334 6 months of age in both intervention and control groups (61) suggesting the limited effect of

335 maternal iron and folic acid supplementations in the form of BEP and IFA tablets
336 formulations. On the other hand, the exploratory analysis here indicated a beneficial role of
337 BEP in mitigating the negative effect of OTA exposure on increased infant anemia at the age
338 of 6 months. To our knowledge, there is no other study addressing the role of nutritional
339 supplementation on the effects of mycotoxins exposure.

340 The high prevalence of OTA exposure in the present study can have severe adverse
341 consequences. After its absorption from the gastrointestinal tract, OTA binds mainly to
342 albumin with high affinity, resulting in its long half-life (62). The OTA mechanism of action
343 is very complex, since it is understood to be carcinogenic, hepatotoxic, immunotoxic,
344 neurotoxic and teratogenic, based on in vitro and on animal studies (63,64). In humans, OTA
345 exposure has been associated with the development of Tunisian Nephropathy (65), gastric and
346 esophageal tumors (66,67), as well as testicular cancer (68). Considering the risks posed by
347 mycotoxins in LMICs, Matumba and colleagues (2021) proposed a framework for prevention
348 and control of mycotoxins in grains. The guideline has five pointers including: i) Sustaining
349 plant's strength and health; ii) Reducing toxigenic fungal population in growing plants and in
350 storage; iii) Rapidly reducing moisture content of grains and avoid rehydration; iv)
351 Safeguarding outer structure of seeds/grains and v) Cleaning and removing mycotoxin high
352 risk components. The guideline also provides recommendation on how grains should be
353 handled from production, harvesting and storage practices all the way to processing
354 considering the factors that promote or prevent fungal contamination and subsequent
355 production of mycotoxins in grains (69).

356 Some of the strengths of the present study include determination of GA using ultrasonography
357 and the assessment of birth outcomes within 12 hours of birth, allowing the timely and robust
358 assessment of study outcomes. The determination of mycotoxin exposure using biomarkers is

359 also superior to the assessment in foodstuffs used in some studies (70). This is also the first
360 application of VAMS for mycotoxin analysis in the whole blood of newborns in an LMIC
361 setting. Considering the benefits of VAMS and the robust method developed, VAMS
362 sampling can be considered as an alternative technique to perform a quantitative screening of
363 mycotoxin exposure (42). The findings also provide support for future studies, using larger
364 cohorts, with sampling using VAMS. In addition, considering the toxicokinetic profiles of the
365 detected mycotoxins, this microsampling technique will further highlight the effect of
366 exposure to mycotoxins on human health, enabling further associations to be made with
367 adverse health outcomes. Lastly, as a limitation, mycotoxin exposure data from only a single
368 time point postnatally was considered. Future studies, using repeated mycotoxins
369 measurements, will provide an insight into the effects of mycotoxins and their
370 physicochemical properties in relation to the timing of exposure. Moreover, further studies
371 assessing mycotoxin exposure during the complementary feeding period in infants and young
372 children will also provide a full picture of the burden of the problem and its effects during the
373 critical window period in this and similar populations.

374 In conclusion, this study reports a high occurrence of newborn OTA exposure and an
375 associated risk of lower birthweight, ponderal index and height growth trajectories in rural
376 Burkina Faso. The findings emphasize the importance of nutrition-sensitive strategies to
377 mitigate dietary OTA in the food supply, as well as adopting food safety measures in LMICs
378 during the fetal period of development.

379 **Data availability request**

380 Given the personal nature of the data, data will be made available through a data-sharing
381 agreement. Please contact carl.lachat@ugent.be and marthe.deboevre@ugent.be for any

382 queries. Supporting study documents, including the study protocol and questionnaires, are
383 publicly available on the study's website: <https://misame3.ugent.be> (accessed on 07
384 December 2023).

385 **Statements and Declarations**

386 **Funding**

387 The MISAME-III main trial work was supported by the Bill & Melinda Gates Foundation
388 (OPP1175213). The mycotoxins sampling and analysis was supported by Fonds
389 Wetenschappelijk Onderzoek (project No G085921N). MDB was supported by the European
390 Research Council under the European Union's Horizon 2020 research and innovation
391 program (grant agreement No 946192, HUMYCO). The funders had no role in the design and
392 conduct of the study; collection, management, analysis, and interpretation of the data; and
393 preparation, review, or approval of the manuscript.

394 **Conflicts of interest**

395 The authors have no relevant financial or non-financial interests to disclose.

396 **Author contributions**

397 Author Contributions: Author Conceptualization: Y.B.-M., A.A., T.D.-C., S.D.S., CL and
398 M.D.B.; Methodology: Y.B.-M., J.E.-H., S.D.S. and M.D.B.; Software: Y.B.-M., A.A., and
399 T.D.-C.; Validation: Y.B.-M., G.D.P, J.E.-H., S.D.S. and M.D.B.; Formal analysis: Y.B.-M
400 and A.A.; Investigation: Y.B.-M., G.D.P, T.D.-C, J.E.-H., L.O., S.D.S. and M.D.B.;;
401 Resources: Y.B.-M., T.D.-C., L.O., L.C.T., S.D.S, C.L. and M.D.B.; Data Curation: Y.B.-M.,
402 A.A., T.D.-C. and L.O.; Writing—Original Draft: Y.B.-M. and A.A.; Writing—Review and
403 Editing: Y.B.-M., A.A., G.D.P, T.D.-C., J.E.-H., L.O., L.C.T., S.D.S., C.L and M.D.B.;

404 Supervision: T.D.-C., S.D.S, C.L., and M.D.B.; Project Administration: Y.B.-M., T.D.-C.,
405 L.O., L.C.T., C.L., S.D.S. and M.D.B.; Funding Acquisition: T.D.-C., C.L. and M.D.B.

406 **Ethical considerations**

407 The study protocol was approved by the Ethical Committee of Ghent University Hospital in
408 Belgium (B670201734334) and the Ethical Committee of Institut de Recherche en Sciences
409 de la Santé in Burkina Faso (50-2020/CEIRES). Written informed consent was obtained from
410 all subjects involved in the study.

411 **Consent to participate**

412 Informed consent was obtained from all subjects involved in the study.

413 **Consent for publication**

414 All the authors also agreed on the publication of this article.

415 **References**

- 416 1. Goessens T, Mouchtaris-Michailidis T, Tesfamariam K, Truong NN, Vertriest F, Bader
417 Y, et al. Dietary mycotoxin exposure and human health risks: A protocol for a systematic
418 review. *Environ Int* [Internet]. 2024 Feb 1 [cited 2024 Feb 2];184:108456. Available
419 from: <https://linkinghub.elsevier.com/retrieve/pii/S0160412024000424>
- 420 2. Abiala MA, Ezekiel CN, Chukwura NI, Odebode AC. Toxigenic *Aspergillus* section
421 *Flavi* and aflatoxins in Dried Yam Chips in Oyo State, Nigeria. *Academia Arena*
422 [Internet]. 2011 [cited 2023 Feb 22];(5):3. Available from: <http://www.sciencepub.net>
- 423 3. Ngum NQ, Babalola OO, Ekwomadu TI, Nleya N, Mulunda M. Six Main Contributing
424 Factors to High Levels of Mycotoxin Contamination in African Foods. *Toxins* 2022, Vol
425 14, Page 318 [Internet]. 2022 Apr 29 [cited 2022 Jul 1];14(5):318. Available from:
426 <https://www.mdpi.com/2072-6651/14/5/318/htm>
- 427 4. Aasa AO, Fru FF, Adelusi OA, Oyeyinka SA, Njobeh PB. A review of toxigenic fungi
428 and mycotoxins in feeds and food commodities in West Africa. *World Mycotoxin J*
429 [Internet]. 2022 Jul 18 [cited 2023 Feb 9];1–16. Available from:
430 <https://www.wageningenacademic.com/doi/10.3920/WMJ2021.2766>
- 431 5. Compaore H, Samandoulougou S, Ware LY, Bambara A, Ratongue H, Sawadogo I, et
432 al. Identification of *Aspergillus* section *Flavi* and *Fumigati* in maize grown in Burkina
433 Faso. *Int J Biosci* [Internet]. 2021 [cited 2023 Dec 21]; Available from:
434 <http://dx.doi.org/10.12692/ijb/18.6.25-36>
- 435 6. Ota E, Ganchimeg T, Morisaki N, Vogel JP, Pileggi C, Ortiz-Panozo E, et al. Risk factors
436 and adverse perinatal outcomes among term and preterm infants born small-for-
437 gestational-age: secondary analyses of the WHO Multi-Country Survey on Maternal and
438 Newborn Health. *PLoS One* [Internet]. 2014 Aug 13 [cited 2023 Aug 4];9(8). Available
439 from: <https://pubmed.ncbi.nlm.nih.gov/25119107/>

- 440 7. Lee SE, Talegawkar SA, Merialdi M, Caulfield LE. Dietary intakes of women during
441 pregnancy in low- and middle-income countries [Internet]. Vol. 16, Public Health
442 Nutrition. 2013. p. 1340–53. Available from:
443 <https://doi.org/10.1017/S1368980012004417>
- 444 8. Abdulrazzaq YM, Osman N, Ibrahim A. Fetal exposure to aflatoxins in the United Arab
445 Emirates. *Ann Trop Paediatr* [Internet]. 2002 [cited 2023 Feb 28];22(1):3–9. Available
446 from: <https://pubmed.ncbi.nlm.nih.gov/11926047/>
- 447 9. Chan-Hon-Tong A, Charles MA, Forhan A, Heude B, Sirot V. Exposure to food
448 contaminants during pregnancy. *Science of The Total Environment*. 2013 Aug 1;458–
449 460:27–35.
- 450 10. Groopman JD, Egner PA, Schulze KJ, Wu LSF, Merrill R, Mehra S, et al. Aflatoxin
451 exposure during the first 1000 days of life in rural South Asia assessed by aflatoxin B1-
452 lysine albumin biomarkers. *Food and Chemical Toxicology*. 2014 Dec 1;74:184–9.
- 453 11. Jonsyn FE, Maxwell SM, Hendrickse RG. Human fetal exposure to ochratoxin A and
454 aflatoxins. *Ann Trop Paediatr* [Internet]. 1995 [cited 2023 Aug 7];15(1):3–9. Available
455 from: <https://pubmed.ncbi.nlm.nih.gov/7598434/>
- 456 12. IARC (International Agency for Research on Cancer). Some naturally occurring
457 substances: heterocyclic aromatic amines and mycotoxins. *IARC Monogr Eval Carcinog*
458 *Risk Chem Hum* [Internet]. 1993 [cited 2023 Feb 8];56(October 1982):397–444.
459 Available from: <https://www.ncbi.nlm.nih.gov/books/NBK513574/>
- 460 13. Godschalk RWL, Kleinjans JCS. Characterization of the exposure-disease continuum in
461 neonates of mothers exposed to carcinogens during pregnancy. *Basic Clin Pharmacol*
462 *Toxicol*. 2008 Feb;102(2):109–17.

- 463 14. Lombard MJ. Mycotoxin Exposure and Infant and Young Child Growth in Africa: What
464 Do We Know? *Ann Nutr Metab* [Internet]. 2014 Oct 1 [cited 2023 Nov 8];64(Suppl.
465 2):42–52. Available from: <https://dx.doi.org/10.1159/000365126>
- 466 15. Woo CSJ, Partanen H, Myllynen P, Vähäkangas K, El-Nezami H. Fate of the teratogenic
467 and carcinogenic ochratoxin A in human perfused placenta. *Toxicol Lett*. 2012 Jan
468 5;208(1):92–9.
- 469 16. Coronel MB, Sanchis V, Ramos AJ, Marin S. Review. Ochratoxin A: presence in human
470 plasma and intake estimation. *Food Sci Technol Int* [Internet]. 2010 Feb [cited 2023 Feb
471 13];16(1):5–18. Available from: <https://pubmed.ncbi.nlm.nih.gov/21339117/>
- 472 17. Bunge I, Dirheimer G, Röschenthaler R. In vivo in vitro inhibition of protein synthesis in
473 *Bacillus stearothermophilus* by ochratoxin A. *Biochem Biophys Res Commun*. 1978 Jul
474 28;83(2):398–405.
- 475 18. Konrad I, Röschenthaler R. Inhibition of phenylalanine tRNA synthetase from *Bacillus*
476 *subtilis* by ochratoxin A. *FEBS Lett*. 1977 Nov 15;83(2):341–7.
- 477 19. Arce-López B, Lizarraga E, Vettorazzi A, González-Peñas E. Human Biomonitoring of
478 Mycotoxins in Blood, Plasma and Serum in Recent Years: A Review. *Toxins* (Basel)
479 [Internet]. 2020 [cited 2023 Oct 2];12(3). Available from:
480 <https://pubmed.ncbi.nlm.nih.gov/32121036/>
- 481 20. Ali N, Hossain K, Degen GH. Blood plasma biomarkers of citrinin and ochratoxin A
482 exposure in young adults in Bangladesh. *Mycotoxin Res* [Internet]. 2018 Mar 1 [cited
483 2023 Sep 13];34(1):59–67. Available from:
484 <https://link.springer.com/article/10.1007/s12550-017-0299-5>
- 485 21. Fan K, Xu J, Jiang K, Liu X, Meng J, Di Mavungu JD, et al. Determination of multiple
486 mycotoxins in paired plasma and urine samples to assess human exposure in Nanjing,
487 China. *Environmental Pollution*. 2019 May 1;248:865–73.

- 488 22. Karima HK, Ridha G, Zied A, Chekib M, Salem M, Abderrazek H. Estimation of
489 Ochratoxin A in human blood of healthy Tunisian population. *Experimental and*
490 *Toxicologic Pathology*. 2010 Sep 1;62(5):539–42.
- 491 23. Tesfamariam K, Argaw A, Hanley-Cook GT, Gebreyesus SH, Kolsteren P, Belachew T,
492 et al. Multiple mycotoxin exposure during pregnancy and risks of adverse birth
493 outcomes: a prospective cohort study in rural Ethiopia. *Environ Int* [Internet]. 2022 Feb
494 [cited 2022 Jan 18];160:107052. Available from:
495 <https://linkinghub.elsevier.com/retrieve/pii/S0160412021006772>
- 496 24. Etzel RA, Zilber JJ. Reducing Malnutrition: Time to Consider Potential Links Between
497 Stunting and Mycotoxin Exposure? *Pediatrics* [Internet]. 2014 Jul 1 [cited 2023 Aug
498 7];134(1):4–6. Available from: [/pediatrics/article/134/1/4/62292/Reducing-](https://pediatrics/article/134/1/4/62292/Reducing-Malnutrition-Time-to-Consider-Potential)
499 [Malnutrition-Time-to-Consider-Potential](https://pediatrics/article/134/1/4/62292/Reducing-Malnutrition-Time-to-Consider-Potential)
- 500 25. Christian P, Lee SE, Angel MD, Adair LS, Arifeen SE, Ashorn P, et al. Risk of childhood
501 undernutrition related to small-for-gestational age and preterm birth in low- and middle-
502 income countries. *Int J Epidemiol* [Internet]. 2013 Oct [cited 2024 Feb 15];42(5):1340–
503 55. Available from: <https://pubmed.ncbi.nlm.nih.gov/23920141/>
- 504 26. Gu H, Wang L, Liu L, Luo X, Wang J, Denis Nkomola P, et al. A gradient relationship
505 between low birth weight and IQ: A meta-analysis OPEN. *SCiEnTifiC RepoRtS* |
506 [Internet]. 2017 [cited 2024 Feb 15];7:18035. Available from:
507 www.nature.com/scientificreports/
- 508 27. Jornayvaz FR, Vollenweider P, Bochud M, Mooser V, Waeber G, Marques-Vidal P. Low
509 birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus
510 study. *Cardiovasc Diabetol*. 2016;15:73.
- 511 28. Tesfamariam K, De Boevre M, Kolsteren P, Belachew T, Mesfin A, De Saeger S, et al.
512 Dietary mycotoxins exposure and child growth, immune system, morbidity, and

- 513 mortality: a systematic literature review. *Crit Rev Food Sci Nutr* [Internet]. 2020 Oct 27
514 [cited 2023 Oct 13];60(19):3321–41. Available from:
515 <https://pubmed.ncbi.nlm.nih.gov/31694387/>
- 516 29. Kyei NNA, Boakye D, Gabrysch S. Maternal mycotoxin exposure and adverse
517 pregnancy outcomes: a systematic review. *Mycotoxin Res* [Internet]. 2020 May 1 [cited
518 2023 Aug 14];36(2):243–55. Available from:
519 <https://pubmed.ncbi.nlm.nih.gov/31989413/>
- 520 30. Gönenç İM, Yılmaz Sezer N, Yılmaz S. Mycotoxin exposure and pregnancy. *Crit Rev*
521 *Toxicol* [Internet]. 2020 Aug 8 [cited 2023 Oct 18];50(7):594–604. Available from:
522 <https://www.tandfonline.com/doi/abs/10.1080/10408444.2020.1803791>
- 523 31. Hassen JY, Debella A, Eyeberu A, Mussa I. Level of exposure to aflatoxins during
524 pregnancy and its association with adverse birth outcomes in Africa: a meta-analysis. *Int*
525 *Health* [Internet]. 2024 Feb 10 [cited 2024 Feb 15];0:1–15. Available from:
526 <https://dx.doi.org/10.1093/inthealth/ihae015>
- 527 32. Kpoda DS, Bandé M, Ouattara AS, Bazié RBS, Compaoré AM, Meda RN, et al.
528 Nutritional, Microbiological, and Toxicological Quality Assessment of Foods Sold in
529 Urban and Suburban Markets in Burkina Faso. <https://home.liebertpub.com/hs>
530 [Internet]. 2022 Aug 11 [cited 2023 Apr 21];20(4):298–307. Available from:
531 <https://www.liebertpub.com/doi/10.1089/hs.2022.0023>
- 532 33. FAO. Worldwide regulations for mycotoxins in food and feed in 2003 [Internet]. 2003
533 [cited 2022 Jul 1]. Available from: <https://www.fao.org/3/y5499e/y5499e0d.htm>
- 534 34. Warth B, Parich A, Atehnkeng J, Bandyopadhyay R, Schuhmacher R, Sulyok M, et al.
535 Quantitation of Mycotoxins in Food and Feed from Burkina Faso and Mozambique
536 Using a Modern LC-MS/MS Multitoxin Method. 2012 [cited 2022 Jul 1]; Available
537 from: <https://pubs.acs.org/sharingguidelines>

- 538 35. Bastos-Moreira Y, Argaw A, Dailey-Chwalibóg T, El-Hafi J, Ouédraogo LO, Toe LC,
539 et al. Prenatal ochratoxin A exposure, birth outcomes and infant growth in rural Burkina
540 Faso: a human biomonitoring sub-study from the MISAME-III trial. medRxiv [Internet].
541 2024 Feb 24 [cited 2024 Feb 26];460:2024.02.23.24303256. Available from:
542 <https://www.medrxiv.org/content/10.1101/2024.02.23.24303256v1>
- 543 36. Vanslambrouck K, De Kok B, Toe LC, De Cock N, Ouedraogo M, Dailey-Chwalibóg T,
544 et al. Effect of balanced energy-protein supplementation during pregnancy and lactation
545 on birth outcomes and infant growth in rural Burkina Faso: study protocol for a
546 randomised controlled trial. BMJ Open [Internet]. 2021 Mar 24 [cited 2023 Nov
547 8];11(3). Available from: <https://pubmed.ncbi.nlm.nih.gov/33762226/>
- 548 37. Bastos-Moreira Y, Ouédraogo L, De Boevre M, Argaw A, de Kok B, Hanley-Cook GT,
549 et al. A Multi-Omics and Human Biomonitoring Approach to Assessing the
550 Effectiveness of Fortified Balanced Energy–Protein Supplementation on Maternal and
551 Newborn Health in Burkina Faso: A Study Protocol. *Nutrients* 2023, Vol 15, Page 4056
552 [Internet]. 2023 Sep 19 [cited 2023 Nov 8];15(18):4056. Available from:
553 <https://www.mdpi.com/2072-6643/15/18/4056/htm>
- 554 38. de Kok B, Moore K, Jones L, Vanslambrouck K, Toe LC, Ouédraogo M, et al. Home
555 consumption of two fortified balanced energy protein supplements by pregnant women
556 in Burkina Faso. *Matern Child Nutr.* 2021;17(3):1–13.
- 557 39. Hanley-Cook G, Argaw A, de Kok B, Toe LC, Dailey-Chwalibóg T, Ouédraogo M, et
558 al. Seasonality and Day-to-Day Variability of Dietary Diversity: Longitudinal Study of
559 Pregnant Women Enrolled in a Randomized Controlled Efficacy Trial in Rural Burkina
560 Faso. *Journal of Nutrition.* 2022;152(9):2145–54.
- 561 40. Villar J, Ismail LC, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International
562 standards for newborn weight, length, and head circumference by gestational age and

- 563 sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. The
564 Lancet. 2014 Sep;384(9946):857–68.
- 565 41. de Onis M, Branca F. Childhood stunting: a global perspective. *Matern Child Nutr*
566 [Internet]. 2016 May 1 [cited 2023 May 16];12 Suppl 1(Suppl 1):12–26. Available from:
567 <https://pubmed.ncbi.nlm.nih.gov/27187907/>
- 568 42. Vidal A, Belova L, Stove C, De Boevre M, De Saeger S. Volumetric Absorptive
569 Microsampling as an Alternative Tool for Biomonitoring of Multi-Mycotoxin Exposure
570 in Resource-Limited Areas. *Toxins (Basel)* [Internet]. 2021 [cited 2021 Nov 10];13(5).
571 Available from: [/pmc/articles/PMC8150583/](https://pubmed.ncbi.nlm.nih.gov/358150583/)
- 572 43. Viera A, Garrett J. Understanding interobserver agreement: the kappa statistic. *Fam Med*.
573 2005;
- 574 44. Pfohl-Leszkowicz A, Manderville RA. Ochratoxin A: An overview on toxicity and
575 carcinogenicity in animals and humans. *Mol Nutr Food Res* [Internet]. 2007 Jan [cited
576 2023 Aug 17];51(1):61–99. Available from:
577 <https://pubmed.ncbi.nlm.nih.gov/17195275/>
- 578 45. Jørgensen K. Occurrence of ochratoxin A in commodities and processed food--a review
579 of EU occurrence data. *Food Addit Contam [Internet]*. 2005 Jan [cited 2024 Feb 7];22
580 Suppl 1(SUPPL. 1):26–30. Available from: <https://pubmed.ncbi.nlm.nih.gov/16332618/>
- 581 46. Somda MK, Dabire Y, Mogmenga I, Ouattara A, Nikiema M, Mihin HB, et al.
582 Assessment of Maize Contamination by Aflatoxin in Burkina Faso: A Review of
583 Methods of Control. *Food Nutr Sci* [Internet]. 2023 [cited 2023 Apr 21];14:135–47.
584 Available from: <https://doi.org/10.4236/fns.2023.142010>
- 585 47. Jonsyn FE, Maxwell SM, Hendrickse RG. Ochratoxin A and aflatoxins in breast milk
586 samples from Sierra Leone. *Mycopathologia* [Internet]. 1995 Aug [cited 2024 Feb
587 7];131(2):121–6. Available from: <https://link.springer.com/article/10.1007/BF01102890>

- 588 48. Mahdavi R, Nikniaz L, Arefhosseini SR, Vahed Jabbari M. Determination of aflatoxin
589 M(1) in breast milk samples in Tabriz-Iran. *Matern Child Health J* [Internet]. 2010 Jan
590 [cited 2023 Oct 13];14(1):141–5. Available from:
591 <https://pubmed.ncbi.nlm.nih.gov/19093194/>
- 592 49. Lauer JM, Natamba BK, Ghosh S, Webb P, Wang JS, Griffiths JK. Aflatoxin exposure
593 in pregnant women of mixed status of human immunodeficiency virus infection and rate
594 of gestational weight gain: a Ugandan cohort study. *Tropical Medicine and International*
595 *Health*. 2020 Sep 1;25(9):1145–54.
- 596 50. McCormick SP, Kato T, Maragos CM, Busman M, Lattanzio VMT, Galaverna G, et al.
597 Anomericity of T-2 toxin-glucoside: Masked mycotoxin in cereal crops. *J Agric Food*
598 *Chem* [Internet]. 2015 Jan 21 [cited 2023 Oct 22];63(2):731–8. Available from:
599 <https://pubs.acs.org/doi/full/10.1021/jf504737f>
- 600 51. Patil RD, Dwivedi P, Sharma AK. Critical period and minimum single oral dose of
601 ochratoxin A for inducing developmental toxicity in pregnant Wistar rats. *Reproductive*
602 *Toxicology*. 2006 Nov 1;22(4):679–87.
- 603 52. Moré J, Galtier P, Alvinerie M, Escribe MJ. Effet embryotoxique et tératogène chez le
604 rat. *Annales de Recherches Vétérinaires* [Internet]. 1974 [cited 2024 Feb 9];5(2):167–
605 78. Available from: <https://hal.science/hal-00900797>
- 606 53. Moré J, Galtier P, Alvinerie M, Brunel-Dubech N. TOXICITE DE L’OCHRATOXINE
607 A. 3. EFFETS PENDANT LES STADES INITIAUX DE LA GESTATION CHEZ LE
608 RAT TOXICITE DE L’OCHRATOXINE A 3. EFFETS PENDANT LES STADES
609 INITIAUX DE LA GESTATION CHEZ LE RAT. *Annales de Recherches Vétérinaires*
610 [Internet]. 1978 [cited 2024 Feb 8]; Available from: <https://hal.science/hal-00900988>
- 611 54. Moré J, Galtier P, Brunel-Dubech N, Alvinerie M, Descendance F S LA, RATTFS
612 INTOXIQUÉES MORÉ P GALTIER Nicole BRUNEL-DUBECH M ALVINERIE DJ.

- 613 Effets du traitement sur la descendance (F1 et F2) des rates intoxiquées. *Annales de*
614 *Recherches Vétérinaires* [Internet]. 1975 [cited 2024 Feb 9];6(4):379–89. Available
615 from: <https://hal.science/hal-00900858>
- 616 55. Lauer JM, Duggan CP, Ausman LM, Griffiths JK, Webb P, Wang JS, et al. Maternal
617 aflatoxin exposure during pregnancy and adverse birth outcomes in Uganda. *Matern*
618 *Child Nutr*. 2019 Apr 1;15(2):e12701.
- 619 56. Tesfamariam K, Gebreyesus SH, Lachat C, Hanley-Cook GT, Roro M, Mengistu YG, et
620 al. Chronic aflatoxin exposure during pregnancy is associated with lower fetal growth
621 trajectories: a prospective cohort from the Butajira Nutrition, Mental Health, and
622 Pregnancy (BUNMAP) Study in rural Ethiopia. *Am J Clin Nutr* [Internet]. 2022 Dec 1
623 [cited 2023 Oct 18];116(6):1634–41. Available from:
624 <https://pubmed.ncbi.nlm.nih.gov/36178051/>
- 625 57. Ferrufino-Guardia E, Chavez-Rico V, Larondelle Y. Ochratoxin a in human breast milk,
626 maternal and placental blood from Cochabamba-Bolivia. 2019 [cited 2024 Feb 20];
627 Available from: <https://www.redalyc.org/articulo.oa?id=91967023005>
- 628 58. Zimmerli B, Dick R. Determination of ochratoxin A at the ppt level in human blood,
629 serum, milk and some foodstuffs by high-performance liquid chromatography with
630 enhanced fluorescence detection and immunoaffinity column cleanup: methodology and
631 Swiss data. *J Chromatogr B Biomed Sci Appl*. 1995 Apr 7;666(1):85–99.
- 632 59. de Kok B, Toe LC, Hanley-Cook G, Argaw A, Ouédraogo M, Compaoré A, et al.
633 Prenatal fortified balanced energy-Protein supplementation and birth outcomes in rural
634 Burkina Faso: A randomized controlled efficacy trial. *PLoS Med* [Internet]. 2022 May
635 13 [cited 2022 Aug 19];19(5):e1004002. Available from:
636 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004002>

- 637 60. Hanley-Cook G, Toe LC, Tesfamariam K, de Kok B, Argaw A, Compaoré A, et al.
638 Fortified Balanced Energy-Protein Supplementation, Maternal Anemia, and Gestational
639 Weight Gain: a Randomized Controlled Efficacy Trial Among Pregnant Women in Rural
640 Burkina Faso. *J Nutr* [Internet]. 2022 Jul 30 [cited 2022 Sep 22]; Available from:
641 <https://academic.oup.com/jn/advance-article/doi/10.1093/jn/nxac171/6652215>
- 642 61. Argaw A, de Kok B, Toe LC, Hanley-Cook G, Dailey-Chwalibóg T, Ouédraogo M, et
643 al. Fortified balanced energy–protein supplementation during pregnancy and lactation
644 and infant growth in rural Burkina Faso: A 2 × 2 factorial individually randomized
645 controlled trial. *PLoS Med* [Internet]. 2023 Feb 1 [cited 2023 Apr 20];20(2):e1004186.
646 Available from:
647 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004186>
- 648 62. Kőszegi T, Poór M. Ochratoxin A: Molecular Interactions, Mechanisms of Toxicity and
649 Prevention at the Molecular Level. *Toxins* 2016, Vol 8, Page 111 [Internet]. 2016 Apr
650 15 [cited 2023 Oct 12];8(4):111. Available from: [https://www.mdpi.com/2072-](https://www.mdpi.com/2072-6651/8/4/111/htm)
651 [6651/8/4/111/htm](https://www.mdpi.com/2072-6651/8/4/111/htm)
- 652 63. el Khoury AE, Atoui A. Ochratoxin A: General Overview and Actual Molecular Status.
653 *Toxins* 2010, Vol 2, Pages 461-493 [Internet]. 2010 Mar 29 [cited 2023 Oct
654 12];2(4):461–93. Available from: <https://www.mdpi.com/2072-6651/2/4/461/htm>
- 655 64. Ringot D, Chango A, Schneider YJ, Larondelle Y. Toxicokinetics and toxicodynamics
656 of ochratoxin A, an update. *Chem Biol Interact*. 2006 Jan 5;159(1):18–46.
- 657 65. Hassen W, Abid-Essafi S, Achour A, Guezzah N, Zakhama A, Ellouz F, et al.
658 Karyomegaly of tubular kidney cells in human chronic interstitial nephropathy in
659 Tunisia: respective role of Ochratoxin A and possible genetic predisposition. *Hum Exp*
660 *Toxicol* [Internet]. 2004 Jul [cited 2023 Oct 12];23(7):339–46. Available from:
661 <https://pubmed.ncbi.nlm.nih.gov/15311851/>

- 662 66. Cui J, Xing L, Li Z, Wu S, Wang J, Liu J, et al. Ochratoxin A induces G(2) phase arrest
663 in human gastric epithelium GES-1 cells in vitro. *Toxicol Lett* [Internet]. 2010 Mar 15
664 [cited 2023 Oct 12];193(2):152–8. Available from:
665 <https://pubmed.ncbi.nlm.nih.gov/20060447/>
- 666 67. Liu J, Wu S, Shen H, Cui J, Wang Y, Xing L, et al. Ochratoxin A induces DNA damage
667 and G2 phase arrest in human esophageal epithelium Het-1A cells in vitro. *J Toxicol Sci*
668 [Internet]. 2015 Sep 10 [cited 2023 Oct 12];40(5):657–65. Available from:
669 <https://pubmed.ncbi.nlm.nih.gov/26354382/>
- 670 68. Schwartz GG. Hypothesis: does ochratoxin A cause testicular cancer? *Cancer Causes*
671 *Control* [Internet]. 2002 [cited 2023 Oct 12];13(1):91–100. Available from:
672 <https://pubmed.ncbi.nlm.nih.gov/11899122/>
- 673 69. Matumba L, Namaumbo S, Ngoma T, Meleke N, De Boevre M, Logrieco AF, et al. Five
674 keys to prevention and control of mycotoxins in grains: A proposal. *Glob Food Sec*. 2021
675 Sep 1;30:100562.
- 676 70. De Boevre M, Jacxsens L, Lachat C, Eeckhout M, Di Mavungu JD, Audenaert K, et al.
677 Human exposure to mycotoxins and their masked forms through cereal-based foods in
678 Belgium. *Toxicol Lett*. 2013 Apr 26;218(3):281–92.
679

Table 1. Characteristics of study participants

Characteristics	All subjects (n=274)	OTA unexposed (n = 169)	OTA exposed (n = 105)
Study health center catchment area			
Boni	43 (15.7)	29 (17.2)	14 (13.3)
Dohoun	35 (12.8)	20 (11.8)	15 (14.3)
Dougoumato II	46 (16.8)	22 (13.0)	24 (22.9)
Karaba	37 (13.5)	18 (10.7)	19 (18.1)
Kari	58 (21.2)	41 (24.3)	17 (16.2)
Koumbia	55 (20.1)	39 (23.1)	16 (15.2)
Household level			
Wealth index, 0 to 10 points	4.70 ± 1.78	4.80 ± 1.75	4.54 ± 1.83
Household food insecurity ^a	192 (70.3)	111(65.7)	81 (77.9)
Improved primary water source ^b	162 (59.1)	102 (60.4)	60 (57.1)
Improved sanitation facility ^c	174 (63.5)	105 (62.1)	69 (65.7)
Household size	6.47 ± 4.64	6.64 ± 4.75	6.18 ± 4.47
Maternal factors			
Age, years	24.26 ± 5.63		
Ethnic group			
Bwaba	156 (56.9)	99 (58.6)	57 (54.3)
Mossi	88 (32.1)	54 (32.0)	34 (32.4)
Others	30 (11.0)	16 (9.4)	14 (13.3)
Religion pregnant women			
Muslim	119 (43.4)	71 (42.0)	48 (45.7)
Protestant	64 (23.4)	35 (20.7)	29 (27.6)
Animist	62 (22.6)	48 (28.4)	14 (13.3)
Catholic	22 (8.0)	11 (6.5)	11 (10.5)
No religion, no animist	5 (1.8)	3 (1.8)	2 (1.9)
Primary education and above	124 (45.3)	80 (48.2)	44 (41.9)
Trimester of pregnancy at enrollment			
First	219 (79.9)	139 (82.2)	80 (76.2)
Second	55 (20.1)	30 (17.8)	25 (23.8)
Parity			
0	69 (25.2)	38 (22.5)	31 (29.5)
1 to 2	105 (38.3)	76 (45.0)	29 (27.6)
≥3	100 (36.5)	55 (32.5)	45 (42.9)
Weight, kg	58.40 ± 9.67	59.24 ± 9.81	57.03 ± 9.32
Height, cm	162.47 ± 5.73	163.01 ± 5.35	161.61 ± 6.23
BMI, kg/m ²	22.09 ± 3.22	22.27 ± 3.34	21.79 ± 3.01
MUAC, mm	261.6 ± 27.9	262.6 ± 28.8	260.0 ± 26.3
Hemoglobin, g/dL	11.69 ± 1.45	11.76 ± 1.42	11.58 ± 1.49
Anemia (Hb < 11 g/dL)	82 (29.9)	47 (27.8)	35 (33.3)
Maternal prenatal supplementation			
BEP + IFA	142 (46.0)	81 (47.9)	44 (41.9)
IFA	167 (54.1)	88 (52.1)	61 (58.1)
Maternal postnatal supplementation			
BEP + IFA	156 (50.5)	94 (55.6)	50 (47.6)
IFA	153 (49.5)	75 (44.4)	55 (52.4)

Data are frequencies (%) or means \pm SD.

^aAssessed using FANTA/USAID's Household Food Insecurity Access Scale.

^bProtected well, borehole, pipe, or bottled water were considered improved water sources.

^cFlush toilet connected to local sewage or septic tank or pit latrine with slab and/or ventilation were considered improved sanitation facilities.

^dHeight of one woman with a physical disability could not be measured.

^e An average food group diversity score was computed from the list-based recalls collected on different days throughout the entire pregnancy. BEP, balanced energy-protein; IFA, iron-folic acid; BMI, body mass index; HB, hemoglobin; MUAC, mid-upper arm circumference; OTA, ochratoxin A.

Table 2. Newborn mycotoxin exposure at birth

Mycotoxins	Positive samples: n (%)	Median (range) µg/L
15-acetyldeoxynivalenol	0.00	<LOD (<LOD, <LOD)
3-acetyldeoxynivalenol	0.00	<LOD (<LOD, <LOD)
aflatoxin B1	1 (0.36)	<LOD (<LOD, 0.34)
aflatoxin B2	0.00	<LOD (<LOD, <LOD)
aflatoxin G1	6 (2.19)	<LOD (<LOD, 0.31)
aflatoxin G2	0.00	<LOD (<LOD, <LOD)
aflatoxin M1	2 (0.73)	<LOD (<LOD, 0.7)
alpha-zearalenol	0.00	<LOD (<LOD, <LOD)
alternariol	0.00	<LOD (<LOD, <LOD)
alternariol monomethyl ether	0.00	<LOD (<LOD, <LOD)
beauvericin	0.00	<LOD (<LOD, <LOD)
beta- zearalenol	0.00	<LOD (<LOD, <LOD)
citrinin	3 (1.1)	<LOD (<LOD, 18.73)
cyclopiazonic acid	0.00	<LOD (<LOD, <LOD)
deepoxy- deoxynivalenol	0.00	<LOD (<LOD, <LOD)
deoxynivalenol -3- glucoside	0.00	<LOD (<LOD, <LOD)
deoxynivalenol	2 (0.73)	<LOD (<LOD, 0.74)
diacetoxyscirpenol	0.00	<LOD (<LOD, <LOD)
enniatin A	0.00	<LOD (<LOD, <LOD)
enniatin A1	0.00	<LOD (<LOD, <LOD)
enniatin B	0.00	<LOD (<LOD, <LOD)
enniatin B1	0.00	<LOD (<LOD, <LOD)
fumonisin B1	0.00	<LOD (<LOD, <LOD)
fumonisin B2	0.00	<LOD (<LOD, <LOD)
fumonisin B3	0.00	<LOD (<LOD, <LOD)
fusarenone-X	0.00	<LOD (<LOD, <LOD)
neosolaniol	0.00	<LOD (<LOD, <LOD)
nivalenol	0.00	<LOD (<LOD, <LOD)
ochratoxin A	105 (38.32)	<LOD (<LOD, 3.61)
ochratoxin alpha	0.00	<LOD (<LOD, <LOD)
roquefortine-C	0.00	<LOD (<LOD, <LOD)
sterigmatocystine	0.00	<LOD (<LOD, <LOD)
T-2-toxin	0.00	<LOD (<LOD, <LOD)
zearalanone	1 (0.36)	<LOD (<LOD, 4.54)
zearalenone	11 (4.01)	<LOD (<LOD, 4.94)

LOD, limit of detection

Table 3: Newborn ochratoxin A exposure and birth outcomes¹

Outcomes	OTA unexposed (n = 169)	OTA exposed (n = 105)	Unadjusted beta (95% CI)	p	Adjusted beta (95% CI)	p
Birthweight, kg	3.10 ± 0.44	2.95 ± 0.41	-0.15 (-0.26, -0.04)	0.006	-0.11 (-0.21, 0.00)	0.042
Low birthweight (<2.5 kg)	14 (8.28)	17 (16.19)	6.19 (-1.69, 14.1)	0.123	4.79 (3.28, 12.9)	0.243
Small-for-gestational age	35 (20.71)	34 (32.38)	10.8 (-0.41, 22.0)	0.059	7.80 (-3.33, 18.9)	0.169
Gestational age, week	40.09 ± 1.20	39.84 ± 1.27	-0.23 (-0.54, 0.07)	0.141	-0.18 (-0.49, 0.12)	0.236
Preterm delivery (<37 week)	3 (1.78)	2 (1.90)	0.09 (-3.26, 3.43)	0.959	-0.17 (-3.85, 3.51)	0.926
Birth length, cm	48.73 ± 2.06	48.49 ± 1.94	-0.38 (-0.86, 0.11)	0.125	-0.18 (-0.67, 0.30)	0.453
MUAC, mm	101.40 ± 8.24	99.59 ± 8.83	-2.27 (-4.26, -0.32)	0.023	-1.71 (-3.6, 0.18)	0.077
Head circumference, cm	33.43 ± 1.51	33.39 ± 1.38	-0.15 (-0.49, 0.20)	0.403	-0.07 (-0.41, 0.27)	0.705
Ponderal index, gm/cm ³	26.68 ± 2.38	25.80 ± 2.48	-0.66 (-1.24, -0.09)	0.023	-0.62 (-1.19, -0.05)	0.034
Chest circumference, cm	32.13 ± 1.62	31.76 ± 1.63	-0.41 (-0.82, -0.01)	0.046	-0.28 (-0.67, 0.11)	0.158

¹Values are mean ± SD or frequencies (percentages). Unadjusted and adjusted beta coefficients are estimated using linear regression models for the continuous outcomes and linear probability models with robust variance estimation for the binary outcomes. All models are adjusted for the health center catchment areas and the prenatal and postnatal interventions arms, while adjusted models additionally contained maternal age, primiparity, baseline BMI and hemoglobin concentration, and household size, wealth index score, access to improved water and sanitation, and food security status. MUAC, mid-upper arm circumference; OTA, ochratoxin A

Table 4. Newborn ochratoxin A exposure and infant growth and nutritional status at 6 months of age¹

Outcomes	OTA unexposed (n = 169)	OTA exposed (n = 105)	Unadjusted beta (95% CI)	<i>p</i>	Adjusted beta (95% CI)	<i>p</i>
Length-for-age Z-score	-0.40 ± 1.12	-0.70 ± 1.17	-0.33 (-0.63, -0.03)	0.031	-0.25 (-0.55, 0.05)	0.105
Weight-for-age Z-score	-0.34 ± 1.07	-0.62 ± 0.99	-0.22 (-0.50, 0.53)	0.113	-0.17 (-0.45, 0.10)	0.218
Weight-for-length Z-score	-0.03 ± 1.03	-0.20 ± 1.02	-0.08 (-0.34, 0.19)	0.569	-0.07 (-0.33, 0.20)	0.607
MUAC, mm	141.11 ± 11.29	139.08 ± 12.50	-2.42 (-5.17, 0.33)	0.085	-2.18 (-4.97, 0.61)	0.125
Head circumference, cm	421.14 ± 15.75	417.84 ± 13.65	-3.37 (-7.18, 0.44)	0.083	-2.90 (-6.76, 0.96)	0.14
Hemoglobin, g/dL	10.32 ± 1.31	10.31 ± 1.14	-0.21 (-0.52, 0.10)	0.187	-0.20 (-0.52, 0.11)	0.204
Stunting	13 (8.23)	10 (10.20)	0.68 (-6.81, 8.16)	0.859	-0.11 (-8.23, 8.00)	0.978
Underweight	7 (4.43)	7 (7.22)	2.00 (-4.53, 8.54)	0.546	2.19 (-4.82, 9.20)	0.539
Wasting	3 (1.90)	3 (3.09)	1.28 (-2.74, 5.30)	0.531	1.53 (-2.57, 5.63)	0.464
Anemia	108 (69.23)	67 (70.53)	6.74 (-4.93, 18.4)	0.257	6.79 (-4.87, 18.4)	0.252

¹Values are mean ± SD or frequencies (percentages). Unadjusted and adjusted betas are estimated using linear regression models for the continuous outcomes and linear probability models with robust variance estimation for the binary outcomes. All models are adjusted for the health center catchment areas and the prenatal and postnatal interventions arms, while adjusted models additionally contained maternal age, primiparity, baseline BMI and hemoglobin concentration, and household size, wealth index score, access to improved water and sanitation, and food security status. MUAC, mid-upper arm circumference; OTA, ochratoxin A.




Figure 1. Study flow diagram of the Biospecimen sub-study (BioSpé) of the MISAME-III project.






Figure 2: Infant growth trajectories from birth to 6 months in OTA unexposed (solid lines; $n = 169$) and exposed (dashed lines; $n = 105$) groups. Mixed-effects models with random intercept for the individual infant and random slope for the child age were fitted to compare OTA exposed and unexposed groups by growth trajectories during first 6 months postpartum. Quadratic models were used for the outcomes height, weight and MUAC and restricted cubic spline model with 4 knots for the outcome head circumference. Fixed effects in the models contained main effect of time, OTA exposure status and time by exposure interaction, which the later evaluates the difference in monthly growth trajectories between exposed and unexposed groups. Additional covariates in the models included the health center catchment areas, the prenatal and postnatal interventions allocation, maternal age, primiparity, baseline BMI and hemoglobin concentration, and household size, wealth index score, access to improved water and sanitation, and food security status. MUAC, mid-upper arm circumference; OTA, ochratoxin A.

a



b



c




Figure 3. UPLC-MS/MS chromatograms of (A) OTA standard solution 2 $\mu\text{g/L}$; (B) OTA-naturally contaminated whole blood microsample (concentration 0.89 $\mu\text{g/L}$); (C) OTA-free whole blood microsample.

Supplemental Table 1: Infant anemia status at 6 months of age by OTA exposure status for the whole study sample and by maternal prenatal supplementation groups¹

Outcomes	OTA unexposed	OTA exposed	Unadj beta (95% CI)	<i>p</i>	Adj beta (95% CI)	<i>p</i>
Overall sample (n = 251)				0.070 ²		0.074 ²
Anemia	108 (69.2)	67 (70.5)	6.74 (-4.93, 18.4)	0.257	6.79 (-4.87, 18.4)	0.252
IFA group (n = 135)						
Anemia	57 (69.5)	42 (79.3)	16.3 (0.95, 31.6)	0.038	18.7 (2.00, 35.3)	0.029
BEP + IFA group (n = 116)						
Anemia	51 (68.9)	25 (59.5)	-4.01 (-21.8, 13.8)	0.657	0.08 (-19.1, 19.3)	0.993

¹Linear probability models with robust variance estimation were used to determine the adjusted and unadjusted differences in anemia status in percentage points and their associated p-values. In the model analyzing the overall sample, the interaction between OTA exposure and the maternal prenatal nutritional supplementation was evaluated by introducing interaction terms with p-values² <0.10 considered as significant interactions. All models are adjusted for the health center catchment areas and the prenatal and postnatal interventions arms, while adjusted models additionally contained maternal age, primiparity, baseline BMI and hemoglobin concentration, and household size, wealth index score, access to improved water and sanitation, and food security status. BEP, balanced energy-protein; IFA, iron-folic acid; OTA, ochratoxin A

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1 (Lines 1-2)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3 (Lines 33-55)
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6 (Lines 59-87)
Objectives	3	State specific objectives, including any prespecified hypotheses	6 (Lines 88-94)
Methods			
Study design	4	Present key elements of study design early in the paper	6-10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-9
		(b) For matched studies, give matching criteria and number of exposed and unexposed	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9 (Lines 121-155)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-11
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-12 (Lines 187-221)
		(b) Describe any methods used to examine subgroups and interactions	10-12 (Lines 187-221)
		(c) Explain how missing data were addressed	N/A
		(d) If applicable, explain how loss to follow-up was addressed	N/A
		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12 (Lines 224-229)
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	12 (Lines 224-225)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12 (Lines 224-229)
		(b) Indicate number of participants with missing data for each variable of interest	N/A
		(c) Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	Report numbers of outcome events or summary measures over time	12-13
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12-13 (Lines 239-255)
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13 (Lines 247-255)
Discussion			
Key results	18	Summarise key results with reference to study objectives	13-14 (Lines 257-266)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18 (Lines 367-373)

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13-18
Generalisability	21	Discuss the generalisability (external validity) of the study results	13-18
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19 (Lines 287-393)

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.